Products


TGSC01AA(4)
Therapeutic Area(s): Anxiety
Phase of Development: Preclinical

Development Status:
Preclinical

Product Description
TGSC01AA is a series of flavonoid compounds which have been shown to have strong anxiolytic properties.

Although benzodiazepines (BDZs) are the safest psychotropic drugs available today and hence widely prescribed as anxiolytics, their sedative, myorelaxant and amnesic actions are often considered unwanted side effects. Other drawbacks of these drugs include recorded instances of ataxia, ethanol and barbiturate increased effects, as well as their potential for drug abuse and tolerance. Most BDZs are also associated with anterograde amnesia. Pretraining administration of BDZs at subataxic doses impairs retention tests performance.

For 40 years scientists have been searching for benzodiazepine-like anxiolytics that lack amnestic, muscle relaxant, anti-convulsant, and sedative properties. This series of compounds may be the answer to that search.

QASAR studies show that TGSC01AA fits into the benzodiazepine receptor site but in a different way than the benzodiazepines.

TGSC01AA has strong anxiolytic activity (up to 30x that of diazepam) without sedative, muscle relaxant, anticonvulsant, and amnestic effects.

TGSC01AA binds strongly to the benzodiazepine receptor, displacing 3H-FNZ. TGSC01AA enhances GABA stimulated chloride influx. In the plus maze test and the punished drinking test TGSC01AA is more active than diazepam predicting strong anxiolytic activity. TGSC01AA has no hypnotic effect. For the lead compound, the ratio between the dose that relieves anxiety and the dose that is hypnotic is 300. For diazepam the ratio is only 3. There is no effect of TGSC01AA on spontaneous locomotor activity in mice. There is no effect on pentylenetetrazol induced seizures. Similarly there are no muscle relaxant or amnestic effects.

In rat toxicity testing, no areas of concern were found up to 100 mg/kg. TGSCO1AA has low bioavailabitlity (<20%), rapid clearance, and hepatic first pass metabolism.

Clinical Trials
No clinical trials have been performed.

Partners
Developmental and marketing partnerships are available.

 
 
 
 
 
 
Fabre-Kramer Pharmaceuticals, Inc.• 5847 San Felipe, Suite 2000• Houston, TX 77057
(713) 975-6900 • Fax (713) 977-1574
Email contact: info@fabrekramer.com
© 2005 Fabre-Kramer Pharmaceuticals, Inc.